Bristol Myers Says Cell Therapy Shows Promise For Heavily Pretreated Blood Cancer Patients

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday shared outcomes from a Phase 2 trial evaluating its experimental cell therapy, arlocabtagene autoleucel (arlo-cel).

The registrational QUINTESSENTIAL study tested this potential first-in-class treatment in adult patients battling quadruple-class exposed relapsed and refractory multiple myeloma.

The company added that as a CAR T cell therapy designed to be administered as a single infusion, arlo-cel potentially represents a differentiated approach for patients with heavily pretreated relapsed and refractory multiple myeloma.

Meeting Critical Trial Endpoints

The clinical study successfully met its primary endpoint. Arlo-cel delivered a statistically significant and clinically meaningful overall response rate in patients who previously received four or more prior lines of therapy.

Furthermore, the clinical trial achieved its key secondary goals. Arlo-cel demonstrated a successful complete response rate for patients with four or more prior lines of therapy.

The experimental therapy also satisfied the overall response rate and complete response rate objectives for patients who completed three or more previous treatments.

Safety Profile And Treatment Method

Arlo-cel operates as an autologous GPRC5D-directed CAR T cell therapy. Doctors administer the therapy as a single infusion, creating a differentiated treatment approach for heavily pretreated multiple myeloma patients.

The complete treatment process requires gathering T cells from the patient’s bloodstream, administering bridging therapy, manufacturing the specific CAR T cells, and applying lymphodepleting chemotherapy prior to the final infusion and safety monitoring period.

Trial investigators found the safety profile of arlo-cel remains consistent with other existing CAR T cell therapies and GPRC5D-targeting options used to treat multiple myeloma.

The pharmaceutical company intends to share the comprehensive results from the QUINTESSENTIAL study during an upcoming medical meeting.

BMY Price Action: Bristol-Myers Squibb shares were down 2.51% at $65.14 at the time of publication on Tuesday, according to Benzinga Pro data.

Image via Shutterstock